Recursion Pharmaceuticals
clinical target proficient ovarian cancer tumor volume increase in rate to durability in combination novel adjacent induces regression alone or with | Recursion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
70 of 143
Related slides by other companies
MAIA Biotechnology
Investor Presentation
January 2024
excellent efficacy in models liver cancer | MAIA Biotechnology
Exscientia
Results
November 2023
induces myeloid differentiation | Exscientia
Chimerix
Investor Presentation
August 2023
agonist distinct molecular target and efficacy profile relative to efficacy in preclinical models of advanced cancers tox studies complete potential to advance to partnerships established for early stage clinical trials with brown university and cancer center preclinical studies are ongoing to evaluate additional oncology indications and predictive for for clinical development pancreatic cancer model shows the potential of | Chimerix
TCR2 Therapeutics
Results
September 2022
survival in ovarian cancer after infusion | TCR2 Therapeutics
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io